FGF-23 Removal is Improved by On-line High-efficiency Hemodiafiltration Compared to Conventional High Flux Hemodialysis

Overview

Journal J Nephrol

Publisher Springer

Specialty Nephrology

Date 2012 May 11

PMID 22573526

Citations 17

Authors

Laure Patrier

Anne-Marie Dupuy

Alexandre Granger Vallee

Lotfi Chalabi

Marion Morena

Bernard Canaud

Jean-Paul Cristol

Affiliations

Soon will be listed here.

Abstract

Background: Reducing circulating levels of fibroblast growth factor-23 (FGF-23) in patients on renal replacement therapy (RRT) could appear as an appealing approach for cardiovascular events prevention. The purpose of our study was to compare the clearance of FGF-23 between high flux hemodialysis (HD) and on-line hemodiafiltration (OL-HDF) procedures.

Methods: Fifty-three patients were included in the HD group while 32 patients were included in the OL-HDF group. Serum pre- and post-dialysis FGF-23 levels were measured using a 2nd generation Human FGF-23 (C-Term) ELISA kit.

Results: Mean FGF-23 reduction rates were significantly higher in OL-HDF (55.7 ± 25.2%) versus HD (36.2 ± 28.6%) groups (P=.0001), as were calculated FGF-23 clearances (P=.015) and Kt/V-FGF-23 (P=.001). Overall, post-treatment FGF-23 levels were significantly lower than pre-treatment values in both groups (P<.01).

Conclusions: OL-HDF achieves higher FGF-23 removal over high flux HD.

Citing Articles

Randomized Trial Demonstrating No Translocation of Intact Intestinal Bacteria During Hemodialysis or Hemodiafiltration.

Rootjes P, Grooteman M, Budding A, Bontkes H, Wijngaarden G, Nube M Kidney Int Rep. 2025; 10(1):109-119.

PMID: 39810793 PMC: 11725968. DOI: 10.1016/j.ekir.2024.09.025.

Left-sided valvular heart disease in dialysis recipients: a single-centre observational study.

Elewa M, Mitra S, Jayanti A Clin Kidney J. 2023; 16(7):1092-1101.

PMID: 37398684 PMC: 10310503. DOI: 10.1093/ckj/sfad020.

High-volume hemodiafiltration decreases the pre-dialysis concentrations of indoxyl sulfate and p-cresyl sulfate compared to hemodialysis: a post-hoc analysis from the HDFit randomized controlled trial.

Lima J, Guedes M, Rodrigues S, Florido A, Moreno-Amaral A, Barra A J Nephrol. 2022; 35(5):1449-1456.

PMID: 35239175 DOI: 10.1007/s40620-022-01283-3.

Fibroblast Growth Factor-23-Klotho Axis in Cardiorenal Syndrome: Mediators and Potential Therapeutic Targets.

Navarro-Garcia J, Gonzalez-Lafuente L, Fernandez-Velasco M, Ruilope L, Ruiz-Hurtado G Front Physiol. 2021; 12:775029.

PMID: 34867481 PMC: 8634640. DOI: 10.3389/fphys.2021.775029.

Change in FGF23 concentration over time and its association with all-cause mortality in patients treated with haemodialysis or haemodiafiltration.

Bouma-de Krijger A, de Roij van Zuijdewijn C, Nube M, Grooteman M, Vervloet M Clin Kidney J. 2021; 14(3):891-897.

PMID: 33777372 PMC: 7986440. DOI: 10.1093/ckj/sfaa028.